Announcement • Aug 02
ChemoMetec Announces CFO Changes, Effective August 3, 2026 ChemoMetec had its board appoint Phillip Massie Price as the new CFO with effect from August 3, 2026. Phillip Massie Price joined ChemoMetec from a position as Director, Corporate Finance at Unimed, a global healthcare group. Previously, he served as Interim Group CFO at LiqTech International Inc., listed on Nasdaq in New York, where he led Group Finance. Phillip is 34 years old, has a background in auditing, and holds an MSc in Business Administration and Auditing from Copenhagen Business School. The board also entered into an agreement with the company's current CFO Kim Nicolajsen that he would resign from his position at the same time as Phillip Massie Price took over. Buy Or Sell Opportunity • Jul 30
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 35% to kr.435. The fair value is estimated to be kr.360, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 26% in 2 years. Earnings are forecast to grow by 45% in the next 2 years. Announcement • May 16
ChemoMetec A/S, Annual General Meeting, Oct 08, 2026 ChemoMetec A/S, Annual General Meeting, Oct 08, 2026. Announcement • May 06
Chemometec A/S Upgrades Earnings Guidance for the Financial Year 2025/2026 ChemoMetec A/S upgraded earnings guidance for the financial year 2025/2026. For the year, the Company now expects revenue in the DKK 505 million - DKK 525 million range, up from DKK 490 million - DKK 520 million in the most recent guidance. To ensure continued compliance with the applicable accounting framework (IFRS), ChemoMetec has adjusted the allocation of revenue between instruments and services. Buy Or Sell Opportunity • May 05
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 48% to kr.303. The fair value is estimated to be kr.391, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 32% in 2 years. Earnings are forecast to grow by 55% in the next 2 years. Valuation Update With 7 Day Price Move • Apr 17
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to kr.349, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total returns to shareholders of 3.4% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.410 per share. Recent Insider Transactions • Mar 29
Deputy Chairman recently bought kr.942k worth of stock On the 26th of March, Hans Glensbjerg bought around 3k shares on-market at roughly kr.281 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Hans' only on-market trade for the last 12 months. Announcement • Mar 26
ChemoMetec A/S Revises Earnings Guidance for the Year 2025/2026 ChemoMetec A/S revised earnings guidance for the year 2025/2026. For the year, the company expects revenue of DKK 490 million to DKK 520 million is now expected in the financial year 2025/26 against the most recently announced DKK 565 million to DKK 580 million. New Risk • Mar 25
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 3.0% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Buy Or Sell Opportunity • Mar 11
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 45% to kr.399. The fair value is estimated to be kr.500, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 50% in 2 years. Earnings are forecast to grow by 83% in the next 2 years. Recent Insider Transactions • Mar 05
Independent Director recently bought kr.199k worth of stock On the 27th of February, Betina Hagerup bought around 483 shares on-market at roughly kr.413 per share. This transaction increased Betina's direct individual holding by 2x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr.1.4m more in shares than they have sold in the last 12 months. Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment deteriorates as stock falls 32% After last week's 32% share price decline to kr.398, the stock trades at a forward P/E ratio of 27x. Average trailing P/E is 32x in the Life Sciences industry in Europe. Total loss to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.442 per share. Reported Earnings • Feb 06
First half 2026 earnings released: EPS: kr.5.40 (vs kr.5.94 in 1H 2025) First half 2026 results: EPS: kr.5.40 (down from kr.5.94 in 1H 2025). Revenue: kr.249.0m (down 1.0% from 1H 2025). Net income: kr.94.0m (down 9.1% from 1H 2025). Profit margin: 38% (down from 41% in 1H 2025). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Feb 06
Chemometec A/S Maintains Earnings Guidance for the Year 2025 ChemoMetec A/S maintained earnings guidance for the year 2025. For the period, the company expects revenue in the range of DKK 565-580 million range. New Risk • Feb 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Recent Insider Transactions • Nov 10
Chief Executive Officer recently bought kr.1.0m worth of stock On the 7th of November, Martin Behrens bought around 1k shares on-market at roughly kr.684 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Martin's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Oct 31
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to kr.796, the stock trades at a forward P/E ratio of 61x. Average trailing P/E is 38x in the Life Sciences industry in Europe. Total returns to shareholders of 18% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.563 per share. Announcement • Oct 28
ChemoMetec A/S Updates Earnings Guidance for the Year 2025-26 ChemoMetec A/S updated earnings guidance for the year 2025-26. For the year, the company now expects revenue to be DKK 565 million - DKK 580 million against the most recently announced DKK 545 million- DKK 565 million. The company expects a positive trend in revenue and profit particularly in the last part of the financial year 2025/26. Announcement • Oct 10
ChemoMetec A/S Approves to Distribute Dividend ChemoMetec A/S at the AGM held on 9 October 2025, approved to distribute a dividend of DKK 7 per share of a nominal value of DKK 1. Declared Dividend • Oct 05
Dividend increased to kr.7.00 Dividend of kr.7.00 is 75% higher than last year. Ex-date: 10th October 2025 Payment date: 14th October 2025 Dividend yield will be 1.0%, which is higher than the industry average of 0.5%. Payout Ratios Payout ratio: 65%. Cash payout ratio: 85%. Valuation Update With 7 Day Price Move • Sep 18
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to kr.646, the stock trades at a forward P/E ratio of 50x. Average trailing P/E is 34x in the Life Sciences industry in Europe. Total returns to shareholders of 3.9% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.523 per share. Announcement • Sep 18
ChemoMetec A/S, Annual General Meeting, Oct 09, 2025 ChemoMetec A/S, Annual General Meeting, Oct 09, 2025, at 17:30 Romance Standard Time. Location: nordsjaellands konferencecenter, gydevang 39-41, 3450 allerod, Denmark Buy Or Sell Opportunity • Sep 17
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 22% to kr.643. The fair value is estimated to be kr.530, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 19% per annum over the same time period. Reported Earnings • Sep 12
Full year 2025 earnings released: EPS: kr.10.71 (vs kr.7.83 in FY 2024) Full year 2025 results: EPS: kr.10.71 (up from kr.7.83 in FY 2024). Revenue: kr.495.6m (up 22% from FY 2024). Net income: kr.186.4m (up 37% from FY 2024). Profit margin: 38% (up from 33% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to kr.427, the stock trades at a forward P/E ratio of 35x. Average trailing P/E is 29x in the Life Sciences industry in Europe. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.304 per share. Reported Earnings • Feb 07
First half 2025 earnings released: EPS: kr.5.94 (vs kr.4.05 in 1H 2024) First half 2025 results: EPS: kr.5.94 (up from kr.4.05 in 1H 2024). Revenue: kr.251.5m (up 26% from 1H 2024). Net income: kr.103.4m (up 47% from 1H 2024). Profit margin: 41% (up from 35% in 1H 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to kr.561, the stock trades at a forward P/E ratio of 54x. Average trailing P/E is 34x in the Life Sciences industry in Europe. Total loss to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.339 per share. Announcement • Jan 10
Chemometec A/S Updates Earnings Guidance for the 2024/2025 Financial Year ChemoMetec A/S updated earnings guidance for the 2024/2025 Financial year. For the year, company expected revenue in the DKK 470 million - DKK 490 million range, up from DKK 460 million - DKK 475 million in the most recent guidance. Announcement • Dec 04
ChemoMetec A/S Updates Earnings Guidance for the Financial Year 2024-2025 ChemoMetec A/S updated earnings guidance for the financial year 2024-2025. For the year, the company now expected revenue to be in the range of DKK 460 million to DKK 475 million, up from DKK 445 million to DKK 460 million in the most recent guidance. Recent Insider Transactions • Nov 12
Deputy Chairman & Senior Advisor recently bought kr.3.2m worth of stock On the 8th of November, Hans Glensbjerg bought around 7k shares on-market at roughly kr.456 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Hans has been a buyer over the last 12 months, purchasing a net total of kr.3.5m worth in shares. Valuation Update With 7 Day Price Move • Nov 08
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to kr.480, the stock trades at a forward P/E ratio of 47x. Average trailing P/E is 40x in the Life Sciences industry in Europe. Total loss to shareholders of 53% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.254 per share. Announcement • Nov 08
ChemoMetec A/S Maintains Earnings Guidance for the Full-Year 2024-2025 ChemoMetec A/S maintained earnings guidance for the full-year 2024-2025. For the year, the company expects revenue to be in the range of DKK 445 million to DKK 460 million. Board Change • Nov 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Chairman Niels Thestrup was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Oct 23
ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA. ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA for €2.8 million on September 20, 2024. A cash consideration of €2.83 million will be paid by ChemoMetec A/S. As part of consideration, €2.83 million is paid towards common equity of Ovizio Imaging Systems NV/SA. For the period ending December 31, 2023, Ovizio Imaging Systems NV/SA reported total revenue of €1.4 million.
ChemoMetec now has three weeks to carry out a due diligence, and if the outcome of this is positive, ChemoMetec will most likely proceed with the acquisition. The transaction is subject to approval of offer by target shareholders, consummation of due diligence investigation and definitive agreement. The tender offer has already been accepted by shareholders owning more than two thirds of Ovizio, and ChemoMetec is currently in the process of obtaining acceptance from the remaining shareholders, who are under a legal obligation to accept. As of October 16, 2024, the deal has been approved by shareholders of Ovizio Imaging Systems NV/SA. Closing is expected to take place within the coming week and will coincide with the actual acquisition date.
ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA on October 22, 2024. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to kr.428, the stock trades at a forward P/E ratio of 48x. Average trailing P/E is 44x in the Life Sciences industry in Europe. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.225 per share. Announcement • Oct 17
ChemoMetec A/S Revises Earnings Guidance for the Financial Year 2024/2025 ChemoMetec A/S revised earnings guidance for the financial year 2024/2025. The company sustained its positive performance in the first quarter of 2024/2025 with better-than-expected sales and order intake. Based on this, the company now expects revenue for the 2024/2025 financial year in the DKK 445 million to DKK 460 million range, up from DKK 435 million to DKK 450 million in the most recent guidance. Announcement • Oct 11
ChemoMetec A/S Approves Dividend ChemoMetec A/S at its Annual General Meeting held on 10 October 2024, approved the proposal of the Board of Directors to distribute a dividend of DKK 4 per share of a nominal value of DKK 1. Upcoming Dividend • Oct 04
Upcoming dividend of kr.4.00 per share Eligible shareholders must have bought the stock before 11 October 2024. Payment date: 15 October 2024. Payout ratio is a comfortable 51% but the company is paying out more than the cash it is generating. Trailing yield: 1.0%. Lower than top quartile of British dividend payers (5.5%). Higher than average of industry peers (0.7%). Announcement • Sep 21
ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA. ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA on September 20, 2024.
For the period ending December 31, 2023, Ovizio Imaging Systems NV/SA reported total revenue of €1.4 million.
The transaction is subject to consummation of due diligence investigation. Declared Dividend • Sep 15
Dividend of kr.4.00 announced Shareholders will receive a dividend of kr.4.00. Ex-date: 11th October 2024 Payment date: 15th October 2024 Dividend yield will be 1.0%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but not covered by cash flows (122% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Sep 12
Full year 2024 earnings released: EPS: kr.7.83 (vs kr.10.27 in FY 2023) Full year 2024 results: EPS: kr.7.83 (down from kr.10.27 in FY 2023). Revenue: kr.407.9m (down 8.2% from FY 2023). Net income: kr.136.3m (down 24% from FY 2023). Profit margin: 33% (down from 40% in FY 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Announcement • Sep 12
ChemoMetec A/S provides earnings guidance for the year 2024/25 ChemoMetec A/S provided earnings guidance for the year 2024/25. For the period, the company expected revenue to be in the DKK 435 million to DKK 450 million range against DKK 407.4 million last year. Valuation Update With 7 Day Price Move • Sep 11
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to kr.427, the stock trades at a forward P/E ratio of 53x. Average trailing P/E is 44x in the Life Sciences industry in Europe. Total loss to shareholders of 54% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.253 per share. Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to kr.357, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 23x in the Life Sciences industry in Europe. Total loss to shareholders of 59% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.232 per share. Announcement • May 25
ChemoMetec A/S Announces CFO Changes The board of ChemoMetec A/S appointed Kim Nicolajsen as new CFO with effect from 1 July 2024. Kim Nicolajsen comes from a similar position as CFO in the family-owned company Rohde Nielsen. He is state-authorized public accountant and has previously worked for KPMG and EY. The board has also entered into an agreement with the company's current CFO Niels Høy Nielsen that he will resign from his position at the same time as Kim Nicolajsen takes over. The board would like to thank Niels Høy Nielsen for his contribution to ChemoMetec and for the good cooperation. CEO Martin Helbo Behrens and CFO Kim Nicolajsen will hereafter form the executive management of ChemoMetec. Recent Insider Transactions • May 16
Independent Director recently bought kr.450k worth of stock On the 13th of May, Peter Reich bought around 1k shares on-market at roughly kr.310 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr.751k more in shares than they have sold in the last 12 months. Valuation Update With 7 Day Price Move • May 15
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to kr.365, the stock trades at a forward P/E ratio of 45x. Average trailing P/E is 36x in the Life Sciences industry in Europe. Total loss to shareholders of 41% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.213 per share. New Risk • Apr 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Apr 13
Now 24% overvalued The stock has been flat over the last 90 days, currently trading at kr.382. The fair value is estimated to be kr.309, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to grow by 32% in 2 years. Earnings are forecast to grow by 33% in the next 2 years. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to kr.311, the stock trades at a forward P/E ratio of 32x. Average trailing P/E is 37x in the Life Sciences industry in Europe. Total loss to shareholders of 55% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.251 per share. Announcement • Apr 13
ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24 ChemoMetec A/S provided earnings guidance for the year 2023/24. For the period, the company expected revenue to be in the DKK 400 million - DKK 415 million range against previously announced DKK 400 million - DKK 435 million and thus still within the most recently announced range. New Risk • Mar 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Announcement • Mar 13
ChemoMetec A/S Announces CEO Changes The Board of Directors of ChemoMetec has decided to appoint the company's current COO Martin Helbo Behrens as new CEO, effective as of March 13, 2024. The decision is based on the Board’s assessment that ChemoMetec in the current phase of the company's development needs a different composition of executive management skills. Therefore, the board has entered into an agreement with the company's current CEO Rasmus Kofoed to resign from his position as of March 13, 2024. Martin Helbo Behrens, who is 31 years old, has been employed at ChemoMetec for a number of years. He was originally employed as part of Group Finance, but in 2021 he relocated to the USA to take up a position as first COO and then CFO of ChemoMetec's American subsidiary. In these roles he has made a significant contribution to ChemoMetec's high growth and commercial success in the North American market over recent years. After almost three years in the USA, Martin Helbo Behrens returned to ChemoMetec's head office in Allerød as Deputy COO in 2023 and took up the position as COO on 1 February 2024. With Martin Helbo Behrens' in-depth insight into ChemoMetec's organization, products and markets, and based on the results he has contributed to creating in ChemoMetec, the Board is convinced that Martin Helbo Behrens will be the right profile to head ChemoMetec as CEO in the future. CEO Martin Helbo Behrens and CFO Niels Høy Nielsen will hereafter form the executive management of ChemoMetec. Valuation Update With 7 Day Price Move • Mar 06
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to kr.541, the stock trades at a forward P/E ratio of 56x. Average trailing P/E is 44x in the Life Sciences industry in Europe. Total returns to shareholders of 2.4% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.249 per share. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to kr.469, the stock trades at a forward P/E ratio of 50x. Average trailing P/E is 45x in the Life Sciences industry in Europe. Total loss to shareholders of 27% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.242 per share. Reported Earnings • Feb 07
First half 2024 earnings released: EPS: kr.4.05 (vs kr.6.06 in 1H 2023) First half 2024 results: EPS: kr.4.05 (down from kr.6.06 in 1H 2023). Revenue: kr.199.8m (down 18% from 1H 2023). Net income: kr.70.6m (down 33% from 1H 2023). Profit margin: 35% (down from 43% in 1H 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Announcement • Feb 06
ChemoMetec A/S Maintains Earnings Guidance for the Year 2024 ChemoMetec A/S maintained earnings guidance for the year 2024. The company maintain full-year guidance for 2023/24 of revenue in the range of DKK 400 million - DKK 435 million and EBITDA in the range of DKK 200 million - DKK 220 million. Announcement • Dec 21
ChemoMetec A/S Announces Executive Changes ChemoMetec A/S announced that COO and deputy chairman of the board Martin Glensbjerg has decided to step down in ChemoMetec to pass the baton on to the next generation. From 1 February 2024 until the end of 2024, he will act as Senior Advisor with reference to CEO Rasmus Kofoed. Martin Glensbjerg continues as deputy chairman of the board. In his new role, Martin Glensbjerg will, among other things, participate in the update of ChemoMetec's strategy and also contribute to ensuring a successful anchoring and launch of the upcoming new products, including XcytoMatic 40 and XcytoMatic 30. At the same time, Martin Helbo Behrens, Deputy COO, is appointed COO, and Bo Melholt Nielsen, Physicist & Project Manager, Chief R&D Officer. Both Martin Helbo Behrens and Bo Melholt Nielsen have been employed at ChemoMetec for a number of years. Before joining as Deputy COO earlier this year, Martin Helbo Behrens was CFO and COO in ChemoMetec's American subsidiary and was part of Group Finance before that. Bo Melholt Nielsen has a strong academic and professional background in physics, especially quantum optics, and as project manager for the development of XcytoMatic 40 and XcytoMatic 30 he has been a significant driving force behind the development of the new generation of products. Martin Glensbjerg was one of three co-founders when ChemoMetec was established in 1997, and since then he has held a leading position in the company and has made a significant contribution to ensuring that ChemoMetec has achieved an attractive global market position. Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment improves as stock rises 29% After last week's 29% share price gain to kr.425, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 31x in the Life Sciences industry in Europe. Total loss to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.295 per share. Valuation Update With 7 Day Price Move • Nov 02
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to kr.302, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 23x in the Life Sciences industry in Europe. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr.312 per share. New Risk • Nov 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (36% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change). Upcoming Dividend • Oct 06
Upcoming dividend of kr.6.00 per share at 1.8% yield Eligible shareholders must have bought the stock before 13 October 2023. Payment date: 17 October 2023. Trailing yield: 1.8%. Lower than top quartile of British dividend payers (6.6%). Higher than average of industry peers (0.9%). Reported Earnings • Sep 14
Full year 2023 earnings released: EPS: kr.10.27 (vs kr.9.16 in FY 2022) Full year 2023 results: EPS: kr.10.27 (up from kr.9.16 in FY 2022). Revenue: kr.444.4m (up 3.7% from FY 2022). Net income: kr.178.7m (up 12% from FY 2022). Profit margin: 40% (up from 37% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. New Risk • Aug 11
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Announcement • May 10
ChemoMetec A/S Affirms Earnings Guidance for the Fiscal Year 2022/2023 ChemoMetec A/S affirmed earnings guidance for the fiscal year 2022/2023. For the year, based on developments in the third quarter of 2022/23, guidance for financial year 2022/23, as announced in connection with the release of the interim report for 2022/23 on 8 February 2023, is maintained. Accordingly, revenue for 2022/23 is expected in the range of DKK 430 million - DKK 460 million. Valuation Update With 7 Day Price Move • May 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to kr.398, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 36x in the Life Sciences industry in Europe. Total returns to shareholders of 30% over the past three years. Reported Earnings • Feb 10
First half 2023 earnings released: EPS: kr.6.06 (vs kr.4.90 in 1H 2022) First half 2023 results: EPS: kr.6.06 (up from kr.4.90 in 1H 2022). Revenue: kr.242.7m (up 16% from 1H 2022). Net income: kr.105.4m (up 24% from 1H 2022). Profit margin: 43% (up from 41% in 1H 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to kr.529, the stock trades at a trailing P/E ratio of 56.9x. Average trailing P/E is 47x in the Life Sciences industry in Europe. Total returns to shareholders of 122% over the past three years. Announcement • Feb 09
ChemoMetec A/S Updates Earnings Guidance for the Fiscal Year 2022/2023 ChemoMetec A/S updated earnings guidance for the fiscal year 2022/2023. For the year, the company expected revenue of DKK 430 million - DKK 460 million, against the previous guidance of DKK 485 million-DKK 505 million. Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment deteriorated over the past week After last week's 18% share price decline to kr.715, the stock trades at a trailing P/E ratio of 76.9x. Average trailing P/E is 42x in the Life Sciences industry in Europe. Total returns to shareholders of 266% over the past three years. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment deteriorated over the past week After last week's 15% share price decline to kr.542, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 32x in the Life Sciences industry in Europe. Total returns to shareholders of 322% over the past three years. Reported Earnings • Sep 17
Full year 2022 earnings released: EPS: kr.9.16 (vs kr.5.08 in FY 2021) Full year 2022 results: EPS: kr.9.16 (up from kr.5.08 in FY 2021). Revenue: kr.428.4m (up 52% from FY 2021). Net income: kr.159.5m (up 81% from FY 2021). Profit margin: 37% (up from 31% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Feb 10
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: EPS: kr.4.90 (up from kr.2.43 in 1H 2021). Revenue: kr.209.8m (up 58% from 1H 2021). Net income: kr.85.2m (up 101% from 1H 2021). Profit margin: 41% (up from 32% in 1H 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 83% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Oct 08
Upcoming dividend of kr.4.00 per share Eligible shareholders must have bought the stock before 15 October 2021. Payment date: 19 October 2021. Trailing yield: 0.2%. Lower than top quartile of British dividend payers (4.1%). Lower than average of industry peers (0.4%). Reported Earnings • Sep 18
Full year 2021 earnings released: EPS kr.5.08 (vs kr.3.51 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: kr.281.1m (up 31% from FY 2020). Net income: kr.88.4m (up 49% from FY 2020). Profit margin: 31% (up from 28% in FY 2020). The increase in margin was driven by higher revenue. Reported Earnings • Feb 07
First half 2021 earnings released: EPS kr.2.43 (vs kr.1.68 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: kr.133.0m (up 28% from 1H 2020). Net income: kr.42.3m (up 54% from 1H 2020). Profit margin: 32% (up from 27% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has increased by 162% per year, which means it is tracking significantly ahead of earnings growth. 
